Develops botulinum toxin-based therapies for debilitating medical conditions, aiming to improve patients' quality of life.
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company specializing in the development of botulinum toxins. The company's primary focus lies in advancing ABP-450 (prabotulinumtoxinA) injection, a promising therapeutic candidate designed to address debilitating medical conditions. ABP-450 has successfully completed Phase 2 studies for treating cervical dystonia and is currently undergoing Phase 2 trials for both chronic and episodic migraine. Additionally, AEON Biopharma is exploring the potential of ABP-450 in treating gastroparesis and posttraumatic stress disorder (PTSD), aiming to broaden its therapeutic applications.
Headquartered in Irvine, California, AEON Biopharma is strategically positioned within the biopharmaceutical landscape, leveraging its innovative approach to botulinum toxin development. The company's commitment to advancing medical science is underscored by its ongoing clinical trials and research initiatives aimed at addressing significant unmet medical needs. Through its dedication to therapeutic innovation, AEON Biopharma aims to improve the lives of patients worldwide, offering new hope in the treatment of challenging medical conditions.
Founded on a mission to transform healthcare through pioneering treatments, AEON Biopharma continues to expand its portfolio and explore new avenues in botulinum toxin therapies. With a steadfast focus on scientific excellence and patient-centered innovation, the company remains dedicated to making impactful contributions to the field of biopharmaceuticals.